Form 4 for JAGX Jaguar Health, Inc.
Accepted 2022-03-30 00:00:00 ET · period of report 2021-09-13 · accession 0001104659-22-040391 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-30 | 2021-09-13 | JAGX | CONTE LISA A | CEO, Pres, Dir | P - Purchase | $2.51 | +7,968 | 8,003 | +22,766% | +$20.0K |
| DM | 2022-03-30 | 2022-03-28 | JAGX | CONTE LISA A | CEO, Pres, Dir | A - Grant | $0.00 | +631.3K | 25.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-13 | P | A | 7,968 | $2.51 | 8,003 | D | — | — | (F1) On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. |
| 2 | Derivative | Restricted stock units | 2022-03-28 | A | A | 606,280 | $0.00 | 606,280 | D | — · — to — | 606,280 Common Stock | (F2) Granted pursuant to the issuer's 2014 Stock Incentive Plan. (F4) The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022. (F3) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F5) The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. |
| 3 | Derivative | Restricted stock units | 2022-03-28 | A | A | 25,000 | $0.00 | 25,000 | D | — · — to — | 25,000 Common Stock | (F2) Granted pursuant to the issuer's 2014 Stock Incentive Plan. (F4) The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022. (F3) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F6) The restricted stock units vest upon (i) successful completion of the pivotal trial of crofelemer (Mytesi) for cancer-therapy related diarrhea and (ii) successful completion of the investigator-initiated trials in support of the proof-of-concept requirement for early access program for patient access in Europe. |